Education
About Us
Working with TipRanks
Follow Us
Artrya Limited (AU:AYA)
ASX:AYA
AYA Stock Chart & Stats
AU$3.23
-AU$0.03(-4.17%)
At close: 4:00 PM EST
AU$3.23
-AU$0.03(-4.17%)
Day’s Range― - ―
52-Week RangeAU$0.56 - AU$5.24
Previous CloseN/A
Volume107.30K
Average Volume (3M)878.02K
Market Cap
AU$510.61M
Enterprise ValueAU$363.25M
Total Cash (Recent Filing)AU$11.33M
Total Debt (Recent Filing)AU$624.00K
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Feb 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding158,084,010
10 Day Avg. Volume1,092,517
30 Day Avg. Volume878,024
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.12
Price to Sales (P/S)2373.98
P/FCF Ratio-4.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$6.27Price Target Upside94.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageArtrya’s low leverage and modest debt provide financial flexibility, extending runway while the company scales commercialization. A conservative capital structure reduces near-term solvency risk and gives management time to pursue clinical adoption and partnerships without immediate refinancing pressure.
Strategic Position In Digital Health / AI Clinical ToolsArtrya operates in structural growth areas: digital health and AI clinical decision support for cardiovascular care. These technologies address persistent demand for improved diagnostic efficiency and outcomes, offering potential durable adoption by hospitals and cardiology services if clinical utility and regulatory acceptance advance.
Initial Commercial Traction (first Meaningful Revenue)Recording initial revenue in FY2025 signals early commercial validation and the start of product monetization. While still small, this transition from pure R&D to revenue generation is a necessary step toward scaling and demonstrates that solutions are progressing beyond trials toward real-world clinical use.
Bears Say
Sustained Cash Burn And Negative Operating Cash FlowConsistent negative operating and free cash flow imply ongoing financing needs and constrain strategic optionality. Persistent cash burn increases dilution or debt risk if revenue growth doesn’t accelerate; it also forces management to prioritize fundraising over long-term commercialization investments.
Deep Negative Margins; No Demonstrated Operating LeverageMaterial negative gross and operating margins reflect heavy investment and very low revenue scale, indicating the business has not yet shown the unit economics or operating leverage needed for sustainable profitability. Scaling is required to convert R&D spend into positive margins.
Declining Equity And Sharply Negative ROEFalling equity and persistently negative ROE signal ongoing value erosion and weaken the financial buffer available to absorb further losses. This dynamic can make future fundraising more dilutive or costly and reduces shareholder upside until the company returns to positive returns on capital.
Artrya Limited News
AYA FAQ
What was Artrya Limited’s price range in the past 12 months?
Artrya Limited lowest share price was AU$0.56 and its highest was AU$5.24 in the past 12 months.
What is Artrya Limited’s market cap?
Artrya Limited’s market cap is AU$510.61M.
When is Artrya Limited’s upcoming earnings report date?
Artrya Limited’s upcoming earnings report date is Feb 24, 2026 which is in 2 days.
How were Artrya Limited’s earnings last quarter?
Artrya Limited released its earnings results on Aug 20, 2025. The company reported -AU$0.086 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.086.
Is Artrya Limited overvalued?
According to Wall Street analysts Artrya Limited’s price is currently Undervalued.
Does Artrya Limited pay dividends?
Artrya Limited does not currently pay dividends.
What is Artrya Limited’s EPS estimate?
Artrya Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Artrya Limited have?
Artrya Limited has 158,084,010 shares outstanding.
What happened to Artrya Limited’s price movement after its last earnings report?
Artrya Limited reported an EPS of -AU$0.086 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.985%.
Which hedge fund is a major shareholder of Artrya Limited?
Currently, no hedge funds are holding shares in AU:AYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artrya Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$6.27 (94.12% Upside)
AU$6.27 (94.12% Upside)
Blogger Sentiment
Bullish
AU:AYA Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
781.57%
12-Months-Change
Fundamentals
Return on Equity
-86.14%
Trailing 12-Months
Asset Growth
24.53%
Trailing 12-Months
Company Description
Artrya Limited
Artrya Limited operates as a medical technology company that uses artificial intelligence (AI) to identify patients at risk of coronary artery disease. It offers Salix, a cloud-based software that uses its AI to automate the detection of coronary artery disease from coronary computed tomography angiography. The company was incorporated in 2018 and is based in West Perth, Australia.
AYA Stock 12 Month Forecast
Average Price Target
AU$6.27
▲(94.12% Upside)
Technical Analysis
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
―
Singular Health Group Ltd
―
HitIQ Limited
―